High level of fluorescent oxidation products and worsening of asthma control over time.
Adult asthma
Asthma control
Epidemiology
Fluorescent oxidation products
Longitudinal study
Oxidative stress
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
06 Sep 2019
06 Sep 2019
Historique:
received:
06
03
2019
accepted:
28
08
2019
entrez:
8
9
2019
pubmed:
8
9
2019
medline:
4
3
2020
Statut:
epublish
Résumé
High Fluorescent oxidation products level (FlOPs), a global oxidative stress biomarker, was associated cross-sectionally with poor asthma outcomes but its longitudinal association with asthma evolution has never been examined. We aimed to study the associations between FlOPs level at baseline and changes in current asthma, asthma attacks and asthma control status over 8 years. We used data from the second survey of the French EGEA cohort study as baseline and the third survey as follow-up. At baseline, the mean age of the 489 participants with ever asthma was 39 (± 16) years, 49% were women. Among participants with controlled asthma at baseline, high FlOPs level was significantly associated with worsening of asthma control at follow-up (odds-ratio adjusted for age, sex and smoking status (95% CI): 2.27 (1.32-3.90). No other significant associations were observed. In conclusion, results suggest FlOPs as a predictor of asthma evolution in adults and a good candidate marker in asthma management.
Identifiants
pubmed: 31492144
doi: 10.1186/s12931-019-1173-0
pii: 10.1186/s12931-019-1173-0
pmc: PMC6731560
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
203Subventions
Organisme : French Agency for Food, Environmental and Occupational Health & Safety; Merck Sharp & Dohme (MSD); the hospital program of clinical research (PHRC)-Paris; the National Research Agency - Health Environment, Health-Work Program; the Region Nord Pas-de-Calais
ID : ANSES/AFSSET, EST- 09-15, PNR-EST 2017; ANR 05-SEST-020-02/05-9-97, ANR CES-2009
Références
Clin Exp Allergy. 1999 Dec;29 Suppl 4:17-21
pubmed: 10641560
Am J Epidemiol. 2007 Sep 1;166(5):544-51
pubmed: 17615090
Am J Epidemiol. 2007 Sep 1;166(5):552-60
pubmed: 17615091
Ann N Y Acad Sci. 2010 Aug;1203:85-91
pubmed: 20716288
Nat Med. 2012 May 04;18(5):716-25
pubmed: 22561835
Am J Nephrol. 2012;36(4):297-304
pubmed: 22986784
Antioxid Redox Signal. 2014 Mar 1;20(7):1126-67
pubmed: 23991888
J Am Heart Assoc. 2013 Oct 08;2(5):e000195
pubmed: 24103570
J Allergy Clin Immunol. 2015 Feb;135(2):299-310; quiz 311
pubmed: 25662302
Lancet. 2015 Sep 12;386(9998):1075-85
pubmed: 26382999
J Allergy Clin Immunol. 2016 Jun;137(6):1709-1716.e6
pubmed: 26688518
Allergy. 2016 Jun;71(6):741-57
pubmed: 26896172
Lancet. 2018 Jan 27;391(10118):350-400
pubmed: 28911920
Eur Respir J. 2017 Dec 28;50(6):
pubmed: 29284685
Clin Exp Allergy. 1995 Nov;25 Suppl 2:19-22
pubmed: 8590334